Patients with colorectal cancer (CRC) with class 3 BRAF mutations should be considered for anti-EGFR antibody treatment, according to a research led by Memorial Sloan Kettering Cancer Center in New York.
The multicentre pooled analysis included patients with non-V600 BRAF-mutated metastatic CRC (mCRC) identified between 2010 and 2017. Mutations were divided into functional classes: activating and RAS-independent (class 2) or kinase-impaired and RAS-dependent (class 3).
A total of 12 patients (30%) with class 2 mutations and 28 with class 3 mutations (70%) received anti-EGFR antibody treatment. No significant differences in clinical characteristics were observed by mutation class.
However, while only one of 12 patients with class 2 BRAF mCRC responded to anti-EGFR therapy, 14 of 28 patients with class 3 BRAF responded (response rate, 8% and 50%, respectively; P=.02). In the first- or second-line setting, one of six (17%) patients with class 2 and seven of nine (78%) patients with class 3 BRAF mutations responded (P=.04). In third- or later-line treatment, none of six patients with class 2 and seven of 19 (37%) patients with class 3 BRAF mutations responded (P=.14).
The authors concluded that patients with CRC with class 3 BRAF mutations should be considered for anti-EGFR antibody treatment.